The global market for Oral Solid Dosage Contract Manufacturing was estimated at US$41.7 Billion in 2024 and is projected to reach US$60.9 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oral Solid Dosage Contract Manufacturing market.
Additionally, increasing regulatory requirements, pricing pressures, and the complexity of formulation development are prompting drug manufacturers to leverage the expertise of specialized CDMOs. The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further fueling demand for OSD pharmaceuticals, driving contract manufacturing partnerships.
Another key advancement is the use of AI and machine learning in formulation optimization and predictive quality control. CDMOs are integrating smart manufacturing technologies to enhance real-time monitoring, reduce production errors, and ensure compliance with Good Manufacturing Practices (GMP). Additionally, the rise of fixed-dose combination (FDC) drugs is driving the need for more sophisticated OSD manufacturing capabilities.
Additionally, the demand for controlled-release and extended-release OSD formulations is growing, requiring CDMOs to expand their expertise in complex formulation techniques. The growing trend of personalized medicine is also influencing OSD manufacturing, as pharma companies explore targeted drug delivery solutions that cater to specific patient needs.
Additionally, the expansion of emerging markets and the increasing prevalence of chronic diseases are fueling demand for affordable and high-quality OSD pharmaceuticals. The rising trend of outsourcing drug production to CDMOs is expected to continue, ensuring steady market growth in the years ahead.
Global Oral Solid Dosage Contract Manufacturing Market - Key Trends & Drivers Summarized
Why Is Contract Manufacturing for Oral Solid Dosage (OSD) Expanding Rapidly?
The oral solid dosage (OSD) contract manufacturing market is experiencing robust growth as pharmaceutical companies seek cost-effective and efficient production solutions. With the rising demand for tablets, capsules, and soft gels in both prescription and over-the-counter (OTC) markets, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) has become a strategic move for pharma companies.Additionally, increasing regulatory requirements, pricing pressures, and the complexity of formulation development are prompting drug manufacturers to leverage the expertise of specialized CDMOs. The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further fueling demand for OSD pharmaceuticals, driving contract manufacturing partnerships.
How Are Technological Advancements Enhancing OSD Contract Manufacturing?
Innovation in manufacturing technology is reshaping the OSD contract manufacturing landscape. Continuous manufacturing, 3D printing, and advanced coating techniques are improving production efficiency, drug bioavailability, and patient compliance. High-speed compression and granulation techniques are enabling large-scale production with improved consistency and quality.Another key advancement is the use of AI and machine learning in formulation optimization and predictive quality control. CDMOs are integrating smart manufacturing technologies to enhance real-time monitoring, reduce production errors, and ensure compliance with Good Manufacturing Practices (GMP). Additionally, the rise of fixed-dose combination (FDC) drugs is driving the need for more sophisticated OSD manufacturing capabilities.
Is the Demand for Specialty and High-Potency OSD Drugs Driving Market Trends?
The increasing focus on specialty pharmaceuticals and high-potency active pharmaceutical ingredients (HPAPIs) is reshaping contract manufacturing trends. CDMOs are investing in specialized containment facilities and advanced equipment to handle potent compounds used in oncology, immunosuppressants, and central nervous system (CNS) treatments.Additionally, the demand for controlled-release and extended-release OSD formulations is growing, requiring CDMOs to expand their expertise in complex formulation techniques. The growing trend of personalized medicine is also influencing OSD manufacturing, as pharma companies explore targeted drug delivery solutions that cater to specific patient needs.
What's Driving the Growth of the Oral Solid Dosage Contract Manufacturing Market?
The growth in the OSD contract manufacturing market is driven by several factors, including the rising demand for cost-effective drug production, increasing regulatory complexity, and the growing need for specialized formulation expertise. The shift toward continuous manufacturing and AI-driven quality control is further enhancing efficiency and scalability.Additionally, the expansion of emerging markets and the increasing prevalence of chronic diseases are fueling demand for affordable and high-quality OSD pharmaceuticals. The rising trend of outsourcing drug production to CDMOs is expected to continue, ensuring steady market growth in the years ahead.
Scope of Study:
The report analyzes the Oral Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Product (Tablets, Capsules, Powders, Granules, Other Products); Mechanism (Controlled Release Mechanism, Immediate Release Mechanism, Delayed Release Mechanism); End-Use (Large Size Companies End-Use, Medium & Small Size Companies End-Use, Other End-Uses)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Tablets segment, which is expected to reach US$30.0 Billion by 2030 with a CAGR of a 7.3%. The Capsules segment is also set to grow at 7.1% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $11.0 Billion in 2024, and China, forecasted to grow at an impressive 6.2% CAGR to reach $9.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Oral Solid Dosage Contract Manufacturing Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Oral Solid Dosage Contract Manufacturing Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Oral Solid Dosage Contract Manufacturing Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AbbVie Contract Manufacturing, Aenova Group, Alcami Corporation, Almac Group, Boehringer Ingelheim International GmbH and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 36 companies featured in this Oral Solid Dosage Contract Manufacturing market report include:
- AbbVie Contract Manufacturing
- Aenova Group
- Alcami Corporation
- Almac Group
- Boehringer Ingelheim International GmbH
- Cambrex Corporation
- Catalent, Inc.
- CMIC Holdings Co., Ltd.
- Corden Pharma International
- Delpharm
- Hetero Labs Limited
- Ind-Swift Laboratories Ltd.
- Jubilant Pharmova Limited
- Lonza Group AG
- NextPharma
- Patheon Pharma Services
- Piramal Pharma Solutions
- Recipharm AB
- Rubicon Research Pvt. Ltd.
- Siegfried Holding AG
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Contract Manufacturing
- Aenova Group
- Alcami Corporation
- Almac Group
- Boehringer Ingelheim International GmbH
- Cambrex Corporation
- Catalent, Inc.
- CMIC Holdings Co., Ltd.
- Corden Pharma International
- Delpharm
- Hetero Labs Limited
- Ind-Swift Laboratories Ltd.
- Jubilant Pharmova Limited
- Lonza Group AG
- NextPharma
- Patheon Pharma Services
- Piramal Pharma Solutions
- Recipharm AB
- Rubicon Research Pvt. Ltd.
- Siegfried Holding AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 172 |
| Published | June 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 41.7 Billion |
| Forecasted Market Value ( USD | $ 60.9 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
